A Phase 2 interventional study of ARO-ANG3 and Placebo in Mixed Dyslipidemia, sponsored by Arrowhead Pharmaceuticals. Completed at 24 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.
Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.
Among the 349 studies in Dyslipidemias with a site in United States, this one is the 118th largest by enrollment of the 316 interventional ones that give a count, is one of 10 that started in 2021, is one of 66 in phase 2, and was the 280th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Connecticut · Sites in United States
Ages 18–64
University of Georgia · Sites in United States
Ages 25–75 · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 76 · Phase 4 23
First in 1976; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 105 across the 316 interventional studies, 140 across the 31 observational. Of the 299 that completed or were terminated, 125 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 349 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 5 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyslipidemias with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
| NCT06382298University of GeorgiaCottonseed Oil Versus Matched PUFA Effects | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 349 studies in Dyslipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will initially receive 2 subcutaneous injections of ARO-ANG3 or placebo. Participants who complete the double-blind treatment period may opt to continue in an open-label extension during which they will receive up to 8 doses of ARO-ANG3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: additional inclusion/exclusion criteria may apply per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
Drug: ARO-ANG3
Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
Drug: ARO-ANG3
Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
Drug: ARO-ANG3
Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period.
Drug: ARO-ANG3 · Drug: Placebo
ARO-ANG3 Injection
Sterile Normal Saline (0.9% NaCl)
Percent Change From Baseline in Fasting TG at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Fasting TG Over Time
Time frame: Baseline, up to Week 36 (double-blind treatment period)
Percent Change From Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Fasting Non-HDL-C Over Time
Time frame: Baseline, up to Week 36 (double-blind treatment period)
Percent Change From Baseline in Fasting Total Apolipoprotein B (ApoB) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Fasting Total ApoB Over Time
Time frame: Baseline, up to Week 36 (double-blind treatment period)
Percent Change From Baseline in Fasting Low-density Lipoprotein-Cholesterol (LDL-C) Using Ultracentrifugation at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Fasting LDL-C Using Ultracentrifugation Over Time
Time frame: Baseline, up to Week 36 (double-blind treatment period)
Percent Change From Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in ANGPTL3 Over Time
Time frame: Baseline, up to Week 36 (double-blind treatment period)
Percent Change From Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at Week 24
Time frame: Baseline, Week 24
Percent Change From Baseline in Fasting HDL-C Over Time
Time frame: Baseline, up to Week 36 (double-blind treatment period)
Plasma Pharmacokinetic (PK) Concentration for ARO-ANG3 Over Time in the Double-Blind Treatment Period
Time frame: Baseline, Day 1: pre-dose, 15 minutes, 1, 3, 6 hours post-dose; Day 2: 24 hours post-dose; Week 12: pre-dose, 15 minutes, 1, 3, 6, 24 hours post-dose (double-blind treatment period)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and/or Serious TEAEs up to Week 24
TEAEs are adverse events (AEs) that occur following IP administration or a pre-existing condition exacerbated following IP administration. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.
Time frame: From first dose of IP up to Week 24
Number of Participants With TEAEs and/or SAEs Over Time in the Double-Blind Treatment Period
Adverse event (AE)=any untoward medical occurrence that does not necessarily have to have a causal relationship with this treatment. TEAEs=AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. Serious adverse event (SAE)= an AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.
Time frame: up to Week 36 (double-blind treatment period)
Number of Participants With AEs and/or SAEs Over Time in the Open-Label Extension (OLE) Period
Adverse event (AE)=any untoward medical occurrence that does not necessarily have to have a causal relationship with this treatment. TEAEs=AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. Serious adverse event (SAE)= an AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.
Time frame: From first dose of study drug in the OLE up to Month 24 (open-label extension)
Percent Change From Baseline in Fasting TG Over Time in the Open Label Extension (OLE) Period
Time frame: Baseline, OLE Baseline, Months 1-24 (open-label extension)
Percent Change From Baseline in Fasting Non-HDL-C Over Time in the Open Label Extension (OLE) Period
Time frame: Baseline, OLE Baseline, Months 1-24 (open-label extension)
Percent Change From Baseline in Fasting Total ApoB Over Time in the Open Label Extension (OLE) Period
Time frame: Baseline, OLE Baseline, Months 1-24 (open-label extension)
Percent Change From Baseline in Fasting LDL-C Using Ultracentrifugation Over Time in the Open Label Extension (OLE) Period
Time frame: Baseline, OLE Baseline, Months 1-24 (open-label extension)
Percent Change From Baseline in ANGPTL3 Over Time in the Open Label Extension (OLE) Period
Time frame: Baseline, OLE Baseline, Months 1-24 (open-label extension)
Percent Change From Baseline in Fasting HDL-C Over Time in the Open Label Extension (OLE) Period
Time frame: Baseline, OLE Baseline, Months 1-24 (open-label extension)
| Milestone | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 51 | 51 | 51 | 51 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 48 | 46 | 47 | 50 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 5 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 13 | 36 | 14 | 39 | 13 | 41 |
| Completed | 0 | 0 | 0 | 0 | 5 | 17 | 3 | 14 | 6 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 8 | 19 | 11 | 25 | 7 | 24 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 7 | 18 | 7 | 19 | 4 | 19 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 2 | 3 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting TG at Week 24 | 7.55 ± 3.774 | -43.67 ± 3.770 | -49.01 ± 3.777 | -55.57 ± 3.726 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Week 4 | 7.00 ± 3.583 | -41.52 ± 3.604 | -52.22 ± 3.658 | -56.21 ± 3.619 |
| Week 8 | 13.58 ± 4.188 | -41.01 ± 4.217 | -47.73 ± 4.250 | -52.55 ± 4.257 |
| Week 12 | 2.17 ± 4.305 | -42.79 ± 4.269 | -41.71 ± 4.274 | -49.84 ± 4.183 |
| Week 16 | 17.18 ± 6.952 | -48.48 ± 6.947 | -51.99 ± 6.942 | -58.73 ± 6.820 |
| Week 20 | 11.54 ± 5.930 | -48.70 ± 5.928 | -52.73 ± 5.942 | -57.97 ± 5.790 |
| Week 24 | 7.55 ± 3.774 | -43.67 ± 3.770 | -49.01 ± 3.777 | -55.57 ± 3.726 |
| Week 28 | 7.24 ± 3.950 | -41.38 ± 3.966 | -43.95 ± 4.039 | -54.39 ± 3.920 |
| Week 36 | -0.43 ± 3.798 | -34.49 ± 3.809 | -38.33 ± 3.850 | -51.63 ± 3.750 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24 | 4.2 ± 3.31 | -25.1 ± 3.31 | -24.6 ± 3.31 | -32.2 ± 3.26 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Week 4 | 5.2 ± 2.51 | -23.5 ± 2.52 | -25.3 ± 2.55 | -32.9 ± 2.50 |
| Week 8 | 3.7 ± 3.02 | -24.4 ± 3.04 | -22.8 ± 3.04 | -30.3 ± 3.02 |
| Week 12 | 3.4 ± 3.06 | -22.8 ± 3.04 | -18.4 ± 3.04 | -28.1 ± 2.97 |
| Week 16 | 2.5 ± 2.86 | -26.8 ± 2.86 | -28.3 ± 2.85 | -37.0 ± 2.81 |
| Week 20 | 0.8 ± 2.71 | -28.1 ± 2.70 | -26.5 ± 2.69 | -34.1 ± 2.64 |
| Week 24 | 4.2 ± 3.31 | -25.1 ± 3.31 | -24.6 ± 3.31 | -32.2 ± 3.26 |
| Week 28 | 1.2 ± 3.00 | -23.1 ± 3.01 | -22.3 ± 3.04 | -30.0 ± 2.96 |
| Week 36 | -1.5 ± 3.19 | -20.2 ± 3.21 | -17.3 ± 3.23 | -24.1 ± 3.14 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting Total Apolipoprotein B (ApoB) at Week 24 | 2.27 ± 2.807 | -16.40 ± 2.835 | -12.91 ± 2.805 | -19.64 ± 2.788 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Week 4 | 2.57 ± 2.074 | -14.00 ± 2.116 | -11.71 ± 2.093 | -18.47 ± 2.105 |
| Week 8 | 1.51 ± 2.518 | -15.85 ± 2.553 | -10.66 ± 2.525 | -15.05 ± 2.556 |
| Week 12 | 2.26 ± 2.656 | -14.96 ± 2.653 | -7.69 ± 2.617 | -15.10 ± 2.606 |
| Week 16 | -1.36 ± 2.524 | -15.72 ± 2.543 | -14.33 ± 2.513 | -21.66 ± 2.509 |
| Week 20 | -0.28 ± 2.350 | -17.99 ± 2.370 | -14.52 ± 2.329 | -18.58 ± 2.326 |
| Week 24 | 2.27 ± 2.807 | -16.40 ± 2.835 | -12.91 ± 2.805 | -19.64 ± 2.788 |
| Week 28 | 0.51 ± 2.688 | -15.39 ± 2.725 | -12.47 ± 2.703 | -17.03 ± 2.680 |
| Week 36 | -2.30 ± 2.777 | -12.85 ± 2.801 | -9.07 ± 2.791 | -13.21 ± 2.756 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting Low-density Lipoprotein-Cholesterol (LDL-C) Using Ultracentrifugation at Week 24 | 5.0 ± 4.53 | -11.0 ± 4.58 | -4.3 ± 4.56 | -15.1 ± 4.51 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Week 4 | 5.1 ± 3.95 | -8.3 ± 4.03 | -3.4 ± 4.02 | -13.7 ± 3.98 |
| Week 8 | 3.7 ± 4.78 | -10.1 ± 4.85 | -0.7 ± 4.83 | -10.8 ± 4.81 |
| Week 12 | 7.7 ± 7.31 | -7.6 ± 7.36 | 7.9 ± 7.34 | -12.1 ± 7.23 |
| Week 16 | 3.6 ± 4.51 | -9.5 ± 4.56 | -7.4 ± 4.52 | -19.5 ± 4.48 |
| Week 20 | 1.8 ± 4.26 | -12.2 ± 4.31 | -6.9 ± 4.28 | -15.3 ± 4.22 |
| Week 24 | 5.0 ± 4.53 | -11.0 ± 4.58 | -4.3 ± 4.56 | -15.1 ± 4.51 |
| Week 28 | 0.2 ± 4.67 | -9.1 ± 4.75 | -2.4 ± 4.74 | -11.3 ± 4.66 |
| Week 36 | 3.1 ± 5.75 | -8.9 ± 5.81 | 3.7 ± 5.82 | -4.4 ± 5.71 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 24 | 1.24 ± 2.801 | -53.02 ± 2.829 | -68.52 ± 2.807 | -72.45 ± 2.761 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Week 4 | 5.54 ± 2.353 | -62.11 ± 2.388 | -75.25 ± 2.401 | -79.15 ± 2.365 |
| Week 8 | 2.97 ± 3.023 | -56.09 ± 3.074 | -69.01 ± 3.066 | -73.47 ± 3.045 |
| Week 12 | 7.38 ± 3.599 | -47.72 ± 3.635 | -63.17 ± 3.608 | -66.62 ± 3.542 |
| Week 16 | 8.48 ± 2.379 | -63.73 ± 2.400 | -75.61 ± 2.379 | -80.52 ± 2.345 |
| Week 20 | 4.35 ± 2.338 | -60.50 ± 2.360 | -73.10 ± 2.347 | -76.25 ± 2.299 |
| Week 24 | 1.24 ± 2.801 | -53.02 ± 2.829 | -68.52 ± 2.807 | -72.45 ± 2.761 |
| Week 28 | 5.18 ± 2.879 | -49.57 ± 2.920 | -61.43 ± 2.921 | -68.19 ± 2.852 |
| Week 36 | 3.73 ± 3.110 | -41.70 ± 3.158 | -53.41 ± 3.155 | -59.85 ± 3.066 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at Week 24 | 3.1 ± 2.91 | -9.0 ± 2.94 | -18.5 ± 2.96 | -21.5 ± 2.89 |
| percentage change | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| Week 4 | -0.3 ± 2.59 | -13.9 ± 2.63 | -25.5 ± 2.68 | -24.8 ± 2.61 |
| Week 8 | 0.4 ± 2.67 | -14.5 ± 2.71 | -25.0 ± 2.74 | -25.8 ± 2.69 |
| Week 12 | 2.0 ± 3.10 | -7.0 ± 3.11 | -18.7 ± 3.14 | -18.2 ± 3.05 |
| Week 16 | 2.1 ± 2.99 | -15.8 ± 3.02 | -28.5 ± 3.04 | -30.2 ± 2.96 |
| Week 20 | 3.4 ± 2.89 | -11.3 ± 2.92 | -25.1 ± 2.94 | -27.1 ± 2.86 |
| Week 24 | 3.1 ± 2.91 | -9.0 ± 2.94 | -18.5 ± 2.96 | -21.5 ± 2.89 |
| Week 28 | 3.0 ± 2.78 | -5.5 ± 2.82 | -14.7 ± 2.87 | -18.6 ± 2.77 |
| Week 36 | 6.4 ± 2.78 | -1.4 ± 2.82 | -13.7 ± 2.86 | -9.4 ± 2.75 |
| ng/mL | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|
| Day 1, Pre-Dose | 0.0000 ± 0.00000 | 2.6685 ± 12.22871 | 0.0000 ± 0.00000 |
| Day 1, 15 Minutes Post-Dose | 57.6941 ± 28.05778 | 63.5267 ± 55.85108 | 154.7823 ± 129.43190 |
| Day 1, 1 Hour Post-Dose | 75.3752 ± 31.39048 | 130.3387 ± 81.73501 | 221.5979 ± 105.15447 |
| Day 1, 3 Hours Post-Dose | 77.9834 ± 34.90982 | 143.7746 ± 79.62215 | 259.2799 ± 144.46149 |
| Day 1, 6 Hours Post-Dose | 83.9751 ± 53.53021 | 152.0097 ± 91.30854 | 280.0843 ± 153.62465 |
| Day 2, 24 Hours Post-Dose | 13.3369 ± 8.85893 | 33.3047 ± 16.31049 | 77.9982 ± 31.94202 |
| Week 12, Pre-Dose | 0.0000 ± 0.00000 | 0.0653 ± 0.27695 | 1.9366 ± 7.74650 |
| Week 12, 15 Minutes Post-Dose | 54.2741 ± 43.95835 | 68.3054 ± 52.28977 | 134.0610 ± 138.22698 |
| Week 12, 1 Hour Post-Dose | 76.2131 ± 34.49650 | 130.2505 ± 52.66507 | 247.9728 ± 112.83368 |
| Week 12, 3 Hours Post-Dose | 78.2496 ± 36.47898 | 152.0302 ± 78.31595 | 304.2006 ± 178.69258 |
| Week 12, 6 Hours Post-Dose | 87.6919 ± 37.30155 | 154.3280 ± 71.93043 | 312.6397 ± 174.86753 |
| Week 12, 24 Hours Post-Dose | 15.3604 ± 13.03807 | 36.2506 ± 18.33432 | 103.1401 ± 60.85616 |
TEAEs are adverse events (AEs) that occur following IP administration or a pre-existing condition exacerbated following IP administration. An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.
| Participants | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| All TEAEs (Including Serious) | 30 | 37 | 29 | 39 |
| Serious TEAEs | 3 | 3 | 0 | 1 |
Adverse event (AE)=any untoward medical occurrence that does not necessarily have to have a causal relationship with this treatment. TEAEs=AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. Serious adverse event (SAE)= an AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.
| Participants | Placebo (Pooled) | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg |
|---|---|---|---|---|
| All Treatment-Emergent Adverse Events (TEAEs) | 35 | 40 | 34 | 42 |
| Treatment-related TEAEs | 8 | 12 | 8 | 12 |
| Serious TEAEs | 4 | 5 | 0 | 1 |
| TEAEs leading to study drug discontinuation | 2 | 0 | 1 | 0 |
| Deaths | 1 | 0 | 0 | 0 |
| Local Injection Site Reactions (LISR) | 1 | 0 | 3 | 2 |
Adverse event (AE)=any untoward medical occurrence that does not necessarily have to have a causal relationship with this treatment. TEAEs=AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. Serious adverse event (SAE)= an AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction.
| Participants | Placebo/ARO-ANG3 50mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200 mg/ARO-ANG3 200 mg |
|---|---|---|---|---|---|---|
| All Treatment-Emergent Adverse Events (TEAEs) | 10 | 27 | 13 | 30 | 10 | 31 |
| Treatment-related TEAEs | 2 | 8 | 4 | 6 | 0 | 6 |
| Serious TEAEs | 3 | 4 | 2 | 5 | 2 | 5 |
| TEAEs leading to study drug discontinuation | 0 | 0 | 1 | 2 | 1 | 1 |
| Deaths | 0 | 0 | 0 | 1 | 0 | 0 |
| percentage change | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|
| Percent Change from Baseline to OLE Baseline/OLE Day 1 | -10.02 ± 8.711 | -34.78 ± 3.941 | -2.09 ± 13.925 | -39.64 ± 3.357 | 7.87 ± 12.061 | -51.88 ± 2.612 |
| Percent Change from Baseline to OLE Month 1 | -43.74 ± 5.555 | -45.32 ± 3.994 | -50.45 ± 7.323 | -52.86 ± 3.051 | -49.57 ± 5.990 | -62.76 ± 2.262 |
| Percent Change from Baseline to OLE Month 2 | -47.14 ± 4.687 | -45.78 ± 4.449 | -48.96 ± 7.586 | -51.51 ± 2.712 | -48.98 ± 6.568 | -58.66 ± 2.135 |
| Percent Change from Baseline to OLE Month 3 | -40.67 ± 5.792 | -42.51 ± 3.294 | -42.05 ± 8.623 | -48.07 ± 3.255 | -40.73 ± 8.993 | -56.59 ± 2.225 |
| Percent Change from Baseline to OLE Month 6 | -45.81 ± 7.065 | -48.67 ± 4.081 | -48.62 ± 7.597 | -46.81 ± 3.828 | -46.34 ± 8.818 | -57.14 ± 2.697 |
| Percent Change from Baseline to OLE Month 12 | -40.57 ± 9.384 | -47.10 ± 3.546 | -52.40 ± 6.578 | -50.56 ± 4.288 | -49.06 ± 3.275 | -58.36 ± 2.110 |
| Percent Change from Baseline to OLE Month 15 | -47.40 ± 6.442 | -47.33 ± 3.969 | -58.81 ± 4.310 | -56.23 ± 2.968 | -44.56 ± 4.440 | -53.57 ± 4.055 |
| Percent Change from Baseline to OLE Month 18 | -48.07 ± 6.892 | -48.48 ± 3.041 | -55.29 ± 5.170 | -55.11 ± 3.039 | -49.25 ± 4.860 | -51.71 ± 4.761 |
| Percent Change from Baseline to OLE Month 21 | -41.86 ± 9.334 | -45.95 ± 3.609 | -58.42 ± 3.043 | -55.23 ± 3.101 | -49.30 ± 4.388 | -47.42 ± 6.810 |
| Percent Change from Baseline to OLE Month 24 | -48.23 ± 11.315 | -53.83 ± 3.490 | -61.61 ± 8.343 | -56.65 ± 3.545 | -51.88 ± 3.705 | -58.96 ± 3.563 |
| percentage change | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|
| Percent Change from Baseline to OLE Baseline/OLE Day 1 | 6.70 ± 13.049 | -19.95 ± 3.532 | -5.02 ± 5.171 | -16.02 ± 3.824 | -2.53 ± 3.750 | -23.12 ± 3.116 |
| Percent Change from Baseline to OLE Month 1 | -14.79 ± 6.493 | -22.99 ± 3.544 | -25.80 ± 4.039 | -25.23 ± 3.912 | -28.13 ± 3.930 | -33.41 ± 3.158 |
| Percent Change from Baseline to OLE Month 2 | -14.70 ± 5.087 | -25.54 ± 3.730 | -22.32 ± 5.340 | -22.98 ± 3.151 | -28.43 ± 4.168 | -30.35 ± 3.013 |
| Percent Change from Baseline to OLE Month 3 | -14.32 ± 6.774 | -20.71 ± 3.770 | -19.61 ± 4.659 | -22.97 ± 3.462 | -25.19 ± 4.215 | -26.68 ± 3.107 |
| Percent Change from Baseline to OLE Month 6 | -10.42 ± 7.330 | -22.11 ± 4.372 | -26.53 ± 4.347 | -24.38 ± 3.392 | -30.83 ± 4.832 | -27.84 ± 3.414 |
| Percent Change from Baseline to OLE Month 12 | -13.72 ± 9.131 | -22.82 ± 4.267 | -24.42 ± 7.159 | -30.48 ± 3.626 | -28.60 ± 3.545 | -30.08 ± 2.731 |
| Percent Change from Baseline to OLE Month 15 | -13.02 ± 13.661 | -24.01 ± 4.257 | -25.66 ± 3.442 | -31.53 ± 3.040 | -25.86 ± 4.405 | -27.73 ± 3.387 |
| Percent Change from Baseline to OLE Month 18 | -23.39 ± 6.010 | -23.26 ± 3.579 | -25.34 ± 4.315 | -33.90 ± 3.422 | -29.09 ± 4.005 | -27.88 ± 3.495 |
| Percent Change from Baseline to OLE Month 21 | -13.13 ± 14.219 | -25.07 ± 3.492 | -34.23 ± 3.783 | -30.46 ± 2.642 | -28.66 ± 4.590 | -25.75 ± 3.735 |
| Percent Change from Baseline to OLE Month 24 | -32.24 ± 14.568 | -27.52 ± 5.126 | -37.23 ± 3.633 | -31.95 ± 4.492 | -24.24 ± 9.558 | -30.82 ± 4.407 |
| percentage change | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|
| Percent Change from Baseline to OLE Baseline/OLE Day 1 | 6.57 ± 8.959 | -13.49 ± 3.086 | -10.22 ± 4.678 | -7.48 ± 2.924 | -3.88 ± 3.080 | -11.77 ± 3.309 |
| Percent Change from Baseline to OLE Month 1 | 6.82 ± NA | — | -1.65 ± NA | -4.45 ± NA | — | -21.63 ± NA |
| Percent Change from Baseline to OLE Month 2 | 0.31 ± 8.213 | -21.00 ± 6.460 | -3.56 ± 6.243 | -7.93 ± 5.968 | -11.37 ± 16.839 | -7.58 ± 6.338 |
| Percent Change from Baseline to OLE Month 3 | -5.48 ± 13.745 | -13.01 ± 7.131 | -0.30 ± 3.518 | -7.09 ± 5.090 | -13.13 ± 4.275 | -8.34 ± 3.722 |
| Percent Change from Baseline to OLE Month 6 | -1.23 ± 7.644 | -13.89 ± 3.645 | -13.84 ± 3.803 | -11.91 ± 3.517 | -18.14 ± 2.810 | -14.04 ± 3.504 |
| Percent Change from Baseline to OLE Month 12 | -3.46 ± 9.733 | -12.63 ± 3.662 | -13.78 ± 6.382 | -15.14 ± 3.520 | -13.87 ± 2.996 | -15.90 ± 2.835 |
| Percent Change from Baseline to OLE Month 15 | -8.08 ± 9.722 | -12.73 ± 3.587 | -13.40 ± 3.056 | -16.23 ± 2.661 | -11.27 ± 4.524 | -13.05 ± 3.530 |
| Percent Change from Baseline to OLE Month 18 | -14.34 ± 5.296 | -13.83 ± 3.624 | -14.12 ± 3.655 | -19.88 ± 2.991 | -13.63 ± 3.819 | -13.92 ± 3.741 |
| Percent Change from Baseline to OLE Month 21 | 0.08 ± 10.835 | -13.42 ± 3.462 | -21.03 ± 3.791 | -15.03 ± 2.910 | -15.70 ± 4.187 | -11.85 ± 3.789 |
| Percent Change from Baseline to OLE Month 24 | -6.57 ± 11.292 | -14.39 ± 5.371 | -24.76 ± 4.680 | -16.73 ± 4.236 | -10.27 ± 8.790 | -18.04 ± 4.441 |
| percentage change | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|
| Percent Change from Baseline to OLE Baseline/OLE Day 1 | 16.61 ± 13.866 | -7.68 ± 4.934 | -1.59 ± 8.079 | 4.59 ± 7.053 | 4.13 ± 5.905 | -2.82 ± 5.633 |
| Percent Change from Baseline to OLE Month 1 | 6.61 ± 8.960 | -4.90 ± 5.203 | -7.43 ± 5.762 | -0.07 ± 7.654 | 3.74 ± 16.591 | -10.01 ± 4.929 |
| Percent Change from Baseline to OLE Month 2 | 5.75 ± 6.546 | -10.81 ± 5.105 | -3.40 ± 7.119 | 7.38 ± 12.473 | 3.50 ± 20.049 | -10.08 ± 4.989 |
| Percent Change from Baseline to OLE Month 3 | 3.79 ± 8.934 | -2.69 ± 5.570 | -2.47 ± 7.839 | 1.94 ± 7.628 | 5.74 ± 20.327 | -1.59 ± 6.358 |
| Percent Change from Baseline to OLE Month 6 | 16.09 ± 11.331 | -2.03 ± 6.503 | -10.68 ± 5.700 | -9.92 ± 4.137 | 3.32 ± 20.431 | -2.80 ± 6.230 |
| Percent Change from Baseline to OLE Month 12 | 6.95 ± 14.056 | -2.77 ± 6.090 | -4.64 ± 9.376 | -8.25 ± 7.573 | 4.05 ± 18.896 | -6.97 ± 4.466 |
| Percent Change from Baseline to OLE Month 15 | 8.54 ± 17.305 | -7.84 ± 6.363 | -6.14 ± 6.380 | -5.41 ± 11.638 | 5.82 ± 18.362 | -7.85 ± 5.264 |
| Percent Change from Baseline to OLE Month 18 | -9.73 ± 8.195 | -5.88 ± 5.801 | -4.52 ± 7.677 | -13.20 ± 7.882 | 6.86 ± 21.962 | -8.43 ± 5.346 |
| Percent Change from Baseline to OLE Month 21 | 9.29 ± 18.925 | -6.14 ± 5.553 | -12.81 ± 7.465 | -4.47 ± 8.744 | -15.64 ± 7.008 | -2.16 ± 5.032 |
| Percent Change from Baseline to OLE Month 24 | -7.17 ± 22.117 | -10.57 ± 6.996 | -12.81 ± 9.496 | -13.83 ± 5.902 | -9.58 ± 14.506 | -6.18 ± 6.423 |
| percentage change | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|
| Percent Change from Baseline to OLE Baseline/OLE Day 1 | 3.41 ± 5.372 | -41.57 ± 4.417 | 4.47 ± 7.595 | -56.81 ± 3.166 | 0.79 ± 4.664 | -59.24 ± 3.551 |
| Percent Change from Baseline to OLE Month 1 | -59.55 ± 3.490 | -65.83 ± 2.836 | -77.02 ± 2.699 | -76.03 ± 1.982 | -74.62 ± 3.753 | -77.96 ± 2.273 |
| Percent Change from Baseline to OLE Month 2 | -53.85 ± 3.393 | -60.01 ± 3.812 | -67.75 ± 4.771 | -71.21 ± 2.367 | -70.19 ± 3.928 | -74.59 ± 2.775 |
| Percent Change from Baseline to OLE Month 3 | -43.36 ± 5.072 | -48.56 ± 6.842 | -61.65 ± 4.510 | -65.54 ± 3.020 | -64.79 ± 5.478 | -68.91 ± 3.310 |
| Percent Change from Baseline to OLE Month 6 | -49.22 ± 5.280 | -54.18 ± 4.076 | -67.23 ± 4.070 | -68.85 ± 2.867 | -69.38 ± 3.736 | -67.04 ± 3.743 |
| Percent Change from Baseline to OLE Month 12 | -55.48 ± 5.056 | -55.20 ± 4.666 | -71.03 ± 4.370 | -69.32 ± 3.691 | -63.23 ± 5.801 | -62.00 ± 4.122 |
| Percent Change from Baseline to OLE Month 15 | -53.01 ± 3.998 | -52.97 ± 4.560 | -65.80 ± 4.669 | -65.28 ± 6.196 | -64.57 ± 3.909 | -55.73 ± 5.734 |
| Percent Change from Baseline to OLE Month 18 | -36.82 ± 9.076 | -39.57 ± 5.638 | -65.71 ± 4.877 | -65.97 ± 3.280 | -61.38 ± 4.943 | -55.31 ± 4.725 |
| Percent Change from Baseline to OLE Month 21 | -40.12 ± 5.814 | -43.45 ± 5.176 | -63.26 ± 4.176 | -64.68 ± 3.414 | -58.10 ± 4.837 | -55.43 ± 4.784 |
| Percent Change from Baseline to OLE Month 24 | -44.08 ± 10.028 | -50.18 ± 6.570 | -48.46 ± 14.321 | -62.95 ± 4.439 | -61.52 ± 3.012 | -63.89 ± 4.009 |
| percentage change | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200mg |
|---|---|---|---|---|---|---|
| Percent Change from Baseline to OLE Baseline/OLE Day 1 | 13.70 ± 6.036 | 1.67 ± 3.360 | 7.70 ± 5.318 | -12.88 ± 3.147 | 4.80 ± 4.562 | -11.26 ± 3.771 |
| Percent Change from Baseline to OLE Month 1 | -10.68 ± 8.416 | -12.31 ± 3.791 | -26.62 ± 4.804 | -28.81 ± 3.214 | -14.33 ± 8.371 | -28.27 ± 3.705 |
| Percent Change from Baseline to OLE Month 2 | -9.46 ± 6.308 | -10.98 ± 3.588 | -19.64 ± 4.846 | -24.78 ± 3.397 | -13.48 ± 7.252 | -28.24 ± 3.362 |
| Percent Change from Baseline to OLE Month 3 | -8.80 ± 5.376 | -9.96 ± 3.318 | -15.50 ± 4.847 | -22.29 ± 3.771 | -12.81 ± 5.209 | -19.78 ± 3.504 |
| Percent Change from Baseline to OLE Month 6 | -8.26 ± 6.279 | -3.95 ± 4.247 | -21.38 ± 6.028 | -26.54 ± 3.486 | -13.75 ± 6.207 | -20.43 ± 4.082 |
| Percent Change from Baseline to OLE Month 12 | -13.83 ± 7.363 | -16.58 ± 3.672 | -22.23 ± 5.893 | -26.51 ± 3.816 | -5.47 ± 5.504 | -18.32 ± 4.314 |
| Percent Change from Baseline to OLE Month 15 | -9.01 ± 6.448 | -12.02 ± 5.116 | -19.76 ± 5.356 | -29.44 ± 3.110 | -14.07 ± 5.004 | -15.04 ± 4.116 |
| Percent Change from Baseline to OLE Month 18 | -10.53 ± 6.499 | -4.80 ± 5.980 | -21.60 ± 5.268 | -28.55 ± 3.462 | -11.86 ± 4.787 | -16.39 ± 4.648 |
| Percent Change from Baseline to OLE Month 21 | -3.87 ± 6.823 | -12.48 ± 3.816 | -22.77 ± 4.713 | -26.12 ± 3.535 | -16.68 ± 2.024 | -17.82 ± 3.788 |
| Percent Change from Baseline to OLE Month 24 | -8.97 ± 10.168 | -11.66 ± 5.293 | -20.28 ± 15.397 | -27.31 ± 4.225 | -16.01 ± 3.759 | -24.10 ± 5.009 |
Collected over All-cause mortality: From randomization through Month 24. Adverse events: From first dose of study drug through Week 36 (double-blind period); from first dose of open-label study drug up to Month 24 (open-label extension).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/51 (2%) | 4/51 (7.8%) | 41/51 (80.4%) |
| ARO-ANG3 50 mg | 0/50 (0%) | 5/50 (10%) | 38/50 (76%) |
| ARO-ANG3 100 mg | 0/51 (0%) | 0/51 (0%) | 41/51 (80.4%) |
| ARO-ANG3 200 mg | 0/52 (0%) | 1/52 (1.9%) | 42/52 (80.8%) |
| Placebo/ARO-ANG3 50 mg | 0/13 (0%) | 3/13 (23.1%) | 10/13 (76.9%) |
| ARO-ANG3 50 mg/ARO-ANG3 50 mg | 0/36 (0%) | 4/36 (11.1%) | 31/36 (86.1%) |
| Placebo/ARO-ANG3 100 mg | 0/14 (0%) | 2/14 (14.3%) | 14/14 (100%) |
| ARO-ANG3 100 mg/ARO-ANG3 100 mg | 1/39 (2.6%) | 5/39 (12.8%) | 34/39 (87.2%) |
| Placebo/ARO-ANG3 200 mg | 0/13 (0%) | 2/13 (15.4%) | 11/13 (84.6%) |
| ARO-ANG3 200mg/ARO-ANG3 200 mg | 0/41 (0%) | 5/41 (12.2%) | 34/41 (82.9%) |
| Event | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/51 | 0/50 | 0/51 | 0/52 | 1/13 | 0/36 | 0/14 | 0/39 | 0/13 | 0/41 |
| Supraventricular tachycardiaCardiac disorders | 0/51 | 0/50 | 0/51 | 0/52 | 1/13 | 0/36 | 0/14 | 0/39 | 0/13 | 0/41 |
| Incarcerated umbilical herniaGastrointestinal disorders | 0/51 | 0/50 | 0/51 | 0/52 | 1/13 | 0/36 | 0/14 | 0/39 | 0/13 | 0/41 |
| Pancreatitis acuteGastrointestinal disorders | 0/51 | 0/50 | 0/51 | 0/52 | 0/13 | 0/36 | 0/14 | 0/39 | 1/13 | 0/41 |
| InfluenzaInfections and infestations | 0/51 | 0/50 | 0/51 | 0/52 | 1/13 | 0/36 | 0/14 | 0/39 | 0/13 | 0/41 |
| PneumoniaInfections and infestations | 0/51 | 0/50 | 0/51 | 0/52 | 0/13 | 0/36 | 1/14 | 0/39 | 1/13 | 0/41 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/51 | 0/50 | 0/51 | 0/52 | 1/13 | 0/36 | 0/14 | 0/39 | 0/13 | 0/41 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/51 | 0/50 | 0/51 | 0/52 | 0/13 | 0/36 | 1/14 | 0/39 | 1/13 | 0/41 |
| Non-cardiac chest painGeneral disorders | 0/51 | 1/50 | 0/51 | 0/52 | 0/13 | 1/36 | 1/14 | 0/39 | 0/13 | 0/41 |
| Acute kidney injuryRenal and urinary disorders | 0/51 | 0/50 | 0/51 | 0/52 | 0/13 | 0/36 | 0/14 | 0/39 | 0/13 | 2/41 |
| Event | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Placebo/ARO-ANG3 50 mg | ARO-ANG3 50 mg/ARO-ANG3 50 mg | Placebo/ARO-ANG3 100 mg | ARO-ANG3 100 mg/ARO-ANG3 100 mg | Placebo/ARO-ANG3 200 mg | ARO-ANG3 200mg/ARO-ANG3 200 mg |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 14/51 | 16/50 | 16/51 | 18/52 | 3/13 | 14/36 | 5/14 | 13/39 | 4/13 | 15/41 |
| Upper respiratory tract infectionInfections and infestations | 7/51 | 8/50 | 9/51 | 11/52 | 1/13 | 6/36 | 3/14 | 9/39 | 2/13 | 9/41 |
| Urinary tract infectionInfections and infestations | 5/51 | 6/50 | 6/51 | 12/52 | 2/13 | 4/36 | 2/14 | 4/39 | 1/13 | 8/41 |
| GastroenteritisInfections and infestations | 4/51 | 0/50 | 1/51 | 2/52 | 0/13 | 0/36 | 3/14 | 1/39 | 0/13 | 2/41 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 5/51 | 4/50 | 2/51 | 7/52 | 0/13 | 3/36 | 3/14 | 2/39 | 1/13 | 7/41 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/51 | 3/50 | 4/51 | 4/52 | 0/13 | 3/36 | 3/14 | 4/39 | 1/13 | 4/41 |
| HeadacheNervous system disorders | 6/51 | 6/50 | 3/51 | 9/52 | 1/13 | 4/36 | 3/14 | 3/39 | 1/13 | 6/41 |
| Back painMusculoskeletal and connective tissue disorders | 1/51 | 5/50 | 2/51 | 8/52 | 0/13 | 5/36 | 0/14 | 2/39 | 1/13 | 8/41 |
| DiarrhoeaGastrointestinal disorders | 3/51 | 2/50 | 4/51 | 4/52 | 0/13 | 1/36 | 1/14 | 4/39 | 2/13 | 4/41 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 3/51 | 2/50 | 1/51 | 2/52 | 2/13 | 2/36 | 1/14 | 1/39 | 0/13 | 2/41 |
| Age, Continuous(years) | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 60.2 ± 11.30 | 60.4 ± 12.68 | 60.0 ± 9.89 | 61.5 ± 12.53 | 60.5 ± 11.58 |
| Sex: Female, Male(Participants) | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Total |
|---|---|---|---|---|---|
| Female | 24 | 25 | 22 | 24 | 95 |
| Male | 27 | 26 | 29 | 27 | 109 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 12 | 18 | 13 | 55 |
| Not Hispanic or Latino | 39 | 39 | 33 | 38 | 149 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Total |
|---|---|---|---|---|---|
| White | 48 | 49 | 49 | 49 | 195 |
| Black or African American | 1 | 1 | 1 | 0 | 3 |
| Asian | 1 | 0 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 1 | 2 |
| Mean Triglycerides (TG) at Baseline(mg/dL) | Placebo | ARO-ANG3 50 mg | ARO-ANG3 100 mg | ARO-ANG3 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 235.15 ± 86.117 | 242.47 ± 79.864 | 246.71 ± 97.996 | 259.97 ± 93.320 | 246.08 ± 89.386 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Aug 2022, 14 months.
Results were first posted in Jan 2024, 1 year 4 months after primary completion.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 14 months is above that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zodasiran